Fundraising FoxImmunocodex
Boston, US · 1 known investors
Find your way into Immunocodex
Sign up to see every warm intro you have to Immunocodex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immunocodex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.
Founders & leadership
MC
Mark CarthyFounder and CEO
FJ
Francisco J. QuintanaScientific Founder
Investors · 1
Pfizer Venture Investmentslisted by Pfizer Venture Investments$5M – $20M
How we know: Pfizer Venture Investments's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Immunocodex do?
- Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases. The company employs a precision approach that aims to re-program immune cells to suppress inflammatory responses while avoiding broad immunosuppression.
- Who founded Immunocodex?
- Immunocodex was founded by Mark Carthy, Francisco J. Quintana.
- Who are Immunocodex's investors?
- Immunocodex's investors include Pfizer Venture Investments.
- Where is Immunocodex headquartered?
- Immunocodex is headquartered in Boston, US.